Pharmaceutical

Catalent backs decentralised manufacture of Galapagos’ CAR-T therapy

Catalent has entered a strategic partnership with Galapagos to facilitate decentralised manufacturing for the latter’s GLPG5101.

Jan 22, 2025 - 06:00
Catalent backs decentralised manufacture of Galapagos’ CAR-T therapy
Catalent has entered a strategic partnership with Galapagos to facilitate decentralised manufacturing for the latter’s GLPG5101.
Read the original article

Tags:

Previous Article

FDA breakthrough status for Bluejay’s CHD therapy brelovitug

Next Article

NVIDIA champions Innophore partnership to model drug dynamics with AI

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Pharmalittle: Lilly expects Medicare to back down on Alzheimer’s drug coverage; key senators change insulin cap proposal

STAT+: Pharmalittle: Lilly expects Medicare to back dow...

Apr 21, 2023

Morning Rounds: Teen pregnancies down, but remain higher in the U.S. 

Morning Rounds: Teen pregnancies down, but remain highe...

Dec 15, 2023

DF-4101 by AbbVie for Head And Neck Squamous Cell Carci...

Apr 21, 2024